Cyclica and Arctoris have expanded their partnership to progress drug discovery programs for novel neurodegenerative targets, focusing on Alzheimer’s disease, according to a press release.
“Cyclica’s platform and capabilities in combination with the biological assay development of Arctoris will enable us to yield meaningful results and advance research development for patients suffering from Alzheimer’s and other neurodegenerative diseases,” Cyclica CEO and President Naheed Kurji, said in the release.
The companies have long-term plans as discussions are already